Scientists discover new biomarker linked to better outcomes of patients with head and neck cancers and non-small cell lung cancer. The work could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.
The findings, which were published this week online ahead of print by the journal Cancer, focus on a protein called Choline phosphate cytidylyltransferase-á CCT-á or CCTá, an "antigen" that prompts the immune system to produce antibodies against it.
Advertisement"Based on what we found, a high CCTá expression appears to be indicative of survival, making CCTá a promising biomarker," said Laura Niedernhofer, a TSRI associate professor who led the study with Gerold Bepler of the Karmanos Cancer Institute. "Our findings suggest that CCTá may, in fact, be more important in determining outcomes in patients with both types of cancer than the already established ERCC1."
The new study, in fact, turns previous studies on ERCC1 on their heads. Dozens of large clinical trials are being conducted using expression of the ERCC1 DNA-repair protein as a determinant of whether patients with lung, pancreatic, gastric, colorectal, esophageal or ovarian cancer should be treated with platinum-based therapy, a very potent but toxic DNA-damaging agent.
However, the new research suggests that these positive results were not actually due to ERCC1, but to CCTá—which also binds to the antibody most frequently used to measure ERCC1 expression. "Our results show CCTá may be a better predictor of patient outcomes than expression of ERCC1," said Niedernhofer.
While ERCC1 is associated with DNA repair, CCTá is involved in the synthesis of a major component of cell membranes, active in membrane-mediated signaling and embryo survival.
The new results were based on an examination of samples from 187 patients with non-small cell lung cancer and 60 patients with head and neck squamous cell carcinomas.
CCTá expression was associated with longer survival rates, including for patients with non-small cell lung cancer who were treated with surgery alone—without the use of platinum-based chemotherapy drugs and associated toxic side effects.